Neuropharmacology, Drugs, Reward Circuitry Flashcards

1
Q

Neurochemistry

A

focuses on the basic chemical composition and processes of the nervous system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Neuropharmacology

A

the study of compounds that selectively affect the nervous system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Receptor Subtypes

A

defined by the pharmacological characteristics of the site and is based on the availability of selective agonists and antagonists for the subtypes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Types of Neurotransmitters:

A

Amine, Amino Acid, Peptide, and Gas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Amine

A

—acetylcholine, dopamine,
serotonin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Amino Acid

A

—GABA, glutamate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Peptide

A

—short chain amino acids
(neuropeptides)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Gas

A

—soluble gases; nitric oxide, carbon
dioxide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Co-Localization (Co-Release)

A

some neurons contain more than one type of neurotransmitter.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

The Main Excitatory Neurotransmitters are

A

Glutamate and Aspartate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Acetylcholine (ACh)

A

First neurotransmitter to be identified

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Cholinergic

A

Neurons that use ACh

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Two types of ACh Receptors

A

Nicotinic and Muscarinic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Nicotinic(nAch)

A

most are inotropic and excitatory, fast and in muscle junctions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Muscarinic

A

G protein-coupled (metabotropic), slower; excitatory or inhibitory

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Nucleus Cholinergic Cell Bodies

A

Basal Forebrain: Nucleus Basalis and the Medial Septal Nucleus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Monoamine Neurotransmitters

A

Catecholamines and Indoleamines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Catecholamines

A

dopamine, epinephrine, and norepinephrine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Indoleamines

A

melatonin and serotonin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Where is Dopamine(DA) found in neurons:

A

Mesostriatral Pathway and Mesolimbocortical DA Pathway

21
Q

Mesostriatal Pathway

A

important in motor control; neuronal loss is a cause of Parkinson’s disease

22
Q

Mesolimbocortical DA pathway

A

involved in reward, reinforcement, and learning; abnormalities are associated with schizophrenia.

23
Q

Serotonin, 5-HT (5-hydroxytryptamine)

A
  • most cell bodies are in raphe nuclei; their serotonergic fibers project widely.
  • Serotonin is implicated in sleep states, mood, sexual behavior, and anxiety.
  • Antidepressants, such as Prozac, increase
    5-HT activity—effects depend on which
    receptor subtypes are affected.
24
Q

Norepinephrine, NE (noradrenaline)

A
  • Released from the locus coeruleus in
    the pons and lateral tegmental system in
    the midbrain
  • Cells producing it are noradrenergic.
  • NE systems modulate processes
    including mood, arousal, and sexual
    behavior.
25
Opioid Peptides
mimic opiate drugs such as morphine (enkephalins and endorphins)
26
Nitric Oxide (NO)
is a gas neurotransmitter that is produced in locations other than axons and not held in vesicles. It does not interact with membrane-bound receptors; diffuses out of and into cells. And it can act as a retrograde transmitter
27
Ligand
a substance that binds to a receptor
28
Agonist
initiates normal effects of the transmitter on that receptor
29
Antagonist
binds to a receptor and does not activate it, prevents binding by other ligands
30
Inverse Agonist
initiates the reverse of the normal affect
31
Competitive Ligands
they bind to the same part of receptor molecule as an endogenous ligand. Can be agonists, antagonists, or inverse agonists
32
Noncompetitive Ligands
bind to modulatory sites that are not part of the receptor complex
33
Binding Affinity
degree of chemical attraction between ligand and receptor - A drug with a high affinity for its receptor will be effective at very low doses. - Neurotransmitters are low-affinity ligands; can rapidly dissociate from receptors.
34
Efficacy
ability of bound ligand to activate the receptor
35
Partial Agonist
produce a medium response regardless of dose
36
Dose-Response Curve (DRC)
graph of the relationship between drug doses and effects
37
Pharmacodynamics
the functional relationship between drugs and their targets
38
Biotransformation
produces active metabolites that may produce side effects.
39
Bioavailable
the extent a substance or drug becomes completely available to its intended biological destination(s) which varies with route of ingestion
40
Pharmacokinetics
factors that affect movement of a drug through the body
41
Blood-brain barrier
Tight junctions within the CNS prevent the movement of large molecules that can limit drug availability. - Many drugs that might be useful are too large to pass the blood-brain barrier to enter the brain.
42
Drug Tolerance
Successive exposures have decreasing effects
43
Metabolic Tolerance
organ systems become more effective at eliminating the drug
44
Functional Tolerance
Target tissue may show altered sensitivity to the drug
45
Down- Regulation
is a reduction in the total number of receptors available to be stimulated due to prolonged receptor activation or fewer receptors available due to agonist drug
46
Up-Regulation
is a cell increase of receptors in response to an agonist
47
Cross-Tolerance
Tolerance to a whole class of chemically similar drugs
48
Withdrawal Symptoms
caused by drug tolerance
49
Sensitization
drug effects that become stronger with repeated treatment